Member Info for technick

Oh AVCT just raised £3.75m, what a surprise. If Genedrive raise more I bet its AFTER they launch a product to market, just saying

Honestly if I could see something then I'd be investing there too, but I don't. They seem to have got a large manufacture on board in then hope that manufacture leads to something sensitive, I have my doubts. I don't doubt that what they produce is specific, but that's a completely different story. GDR uses tried and tested qPCR chemistry, the go-to method of the international groups like WHO, CDC etc. My money (quite literally) is here with GDR, less risk in these times of speed and need, I wouldn't bank on something untried and untested

Yes, but the evidence is they've never achieved a diagnostic test before, so what's different apart from the need... it would be different if they already has diagnostic tests out there, I don't see any

I looked to see if AVCT has published any diagnostic application of their affirmer test, even for flu or something easy. Their Zika references are for the production of their agent, I don't see any saliva based rapid diagnostic test data. Can anyone? Please share!

not the same. Genedrive is a qPCR test, ultimately more sensitive than direct detection like antigen or AVCT's test. They both have their place but they will test fro different things. Have you got it or have you had it. qPCR is the most sensitive test out there, if you have just one viral RNA target in the sample you'll probably detect it!

... that this is this due to people who have missed the Novacyt boat and see GDR as an alternative, surely a bigger upside potential as Novacyt's market cap already much higher than in December before the pandemic. Larger gains here IF / when the products are ready. Remember two products here, the 96 well plate and then the point of care platform and test.

I guess the issue is other platforms out there over the last 20 years have done an excellent job at consolidating the market and bringing expectations around pricing down. No matter how good this is the market now sees these types of tests as low cost. I'd be looking at different ways to make money rather than the initial outlay. Totally doable these days where data is the key to success.

It's a big raise and needed to be done at a discount to current SP. Good for a non-covid platform to get funding in this environment so credit to the board in my opinion. Going to be a while to get a return

Hi dogdays, just view this as a long term investment. With the non-covid products the business is undervalued in my opinionated will come good at a multiple of the current share price so just play the long game. IF they deliver their COVID tests (and they've delivered tests before so there's no reason not to be confident) then the upside is even better. All in my opinion.

Scart, I agree, if Genedrive gets their test out they'll also have the same RNS's. Genedrive already working with WHO and FIND on their HCV approvals so the platform is known. Test and platform RNS please :)!

I'm pretty relaxed. There will be more than one supplier from a continuity of supply perspective and the problem is Novacyt can only grow so much, once they do then people will need to find alternative shares fro growth and we have a long way to go, plus as well as a test that directly competes with Novacyt but pre-dosed into plates used in high throughout labs, we also have the same test on a point of care portable Genedrive. Our day will come! LTHs hold

Agree, the Novacyt rns re U.K. testing was only that they’re in the mix to be evaluated

just to be clear, the project requirement for testing is 250k tests per day. At that rate it would still take 9 months to test the entire country, they are suggesting everyone gets tested multiple times! If that's through there would be a requirement for 130M tests... that's a huge challenge. Most of that will be high throughout labs (Genedrive 96 SARS-CoV-2 plates) and a smaller number would be Genedrive POC, that would be done in emergency settings I would have thought. But 130M tests UK only, that would be incredible!

Hi Piller, in terms of a balanced view I take an opposite position. Long term holder for many years. I've not ever sold. I recognise the investment the business has made in the technology and the markets the business is trying to access. It has one of the only truly portable PCR machines on the market, the others are Roche and Cepheid. Genedrive is targeting a mixture of diseases, each is worth a multiple to todays share price. We now have 3 tests on market, HCV, AIHL and the DOD with the forth revised TB test also coming on line. The brokers target price was 95p and revised down to 60p to take into account the delayed sales for HCV. We are sat at 25p. There is an argument to say we are undervalued at todays price, my opinion is that we are. Then you have COVID19. If you allow £10 per test even a small lab at 1,000 samples per day would generate £3.5m per year in turnover. We are talking about up to 250k per day, almost £1Bn, in the UK... What Genedrive offers IF they are successful is the lab based test and the same test run on an ultra portable unit. So agree it is an IF, but they have delivered before and it's in their sweet spot so you have to have confidence. Genedrive is already in market and selling into the NHS. Let's say they have 10% of the £1bn market. Thats £100m of sales in the UK. The numbers really do put a massive upside to the share. There will be a number of UK suppliers, it makes sense in terms of continuity of supply. Genedrive will be in the mix.

... if GDR get their Covid test out the SP will be significantly higher, if not then the business is still under valued in my view, or at least when sales are apparent the SP will climb from this position. LTH and happy to wait.

This will be modulated by the MM until news comes, the 8-week period was a gift to swing the SP until the next RNS. If they are successful they'll have a great set of products for COIVD on the market and SP will be up at £1, £2.... expect news about half way through the 8 weeks I would have thought, or before if they get grant funding

Thanks guys, I guess they make their dollar somewhere but seems like the ordinary shareholder may get the rough deal in these small cap businesses. Been in this share a while, it will go up as the news we all know is coming is released.

Are the selling to buyers at >30p and dropping the price to fill that order at <30p to pocket the difference? Just interested why those trades took over 24 hours to appear. I’m sure it’s all above board...

So are these orders that were placed on the 2nd and filled by the 3rd? I don’t understand these late showing trades and how they are reported late by the MM?

Significantly less trading today compared to previous days. If people were selling volume surely would be higher, so the drop is on fewer trades, therefore MM dropping the price. If the MM raised the price the volume would be higher. My opinion.